Too many of my Twitter interactions with biotech-loving retail investors are unpleasant. If I write an article raising doubts about a small drugmaker’s clinical trial results, or if I call out misleading statements made by an overly promotional biotech CEO, the responses I receive from people who own the stock generally run the gamut from “f—k you, you clueless a–hole” to “I hope you get cancer and die.”
And sometimes, the replies to my work get really nasty.
Create a display name to comment
This name will appear with your comment